



## Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

January 20, 2022

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- [Cue Biopharma, Inc.](#) (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's [website](#).

Members of the Cue Biopharma executive management team will provide an update from the Company's ongoing clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The discussion will focus on recent data updates from the Phase 1b monotherapy dose expansion trial and the dose escalation combination trial evaluating CUE-101 front line with Merck's KEYTRUDA® (pembrolizumab). Management will also provide an update on the Company's pipeline development progress from the IL-2 based CUE-100 series including CUE-102, with an Investigational New Drug (IND) filing planned for the first quarter of 2022, as well as updates on its strategic objectives and anticipated milestones.

### Webcast Details

**Wednesday, January 26, 2022 at 4:30 p.m. EST**

**Investors:** 877-407-9208

**International:** 201-493-6784

**Conference ID:** 13726509

**Webcast:** [https://viavid.webcasts.com/starthere.jsp?ei=1525411&tp\\_key=7a7d92f501](https://viavid.webcasts.com/starthere.jsp?ei=1525411&tp_key=7a7d92f501)

### About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious disease and autoimmune disease. The company's proprietary Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) platform is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit [www.cuebiopharma.com](http://www.cuebiopharma.com) and follow us on Twitter at <https://twitter.com/CueBiopharma>.

### Investor Contact

George B. Zavoico, Ph.D.

VP, Investor Relations & Corporate Development

Cue Biopharma, Inc.

[gzavoico@cuebio.com](mailto:gzavoico@cuebio.com)

### Media Contact

Darren Opland, Ph.D.

LifeSci Communications

[darren@lifescicomms.com](mailto:darren@lifescicomms.com)



Source: Cue Biopharma, Inc.